Inhaled Corticosteroids in Adults with Non-cystic Fibrosis Bronchiectasis: From Bench to Bedside. A Narrative Review.
Journal
Drugs
ISSN: 1179-1950
Titre abrégé: Drugs
Pays: New Zealand
ID NLM: 7600076
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
accepted:
20
09
2022
pubmed:
21
10
2022
medline:
4
11
2022
entrez:
20
10
2022
Statut:
ppublish
Résumé
Due to their potent anti-inflammatory capacity (particularly in predominantly eosinophilic inflammation) and immunosuppressive properties, inhaled corticosteroids (ICSs) are widely used in asthmatic patients and also in individuals with chronic obstructive pulmonary disease (COPD) who suffer multiple exacerbations or have peripheral eosinophilia. However, there is little evidence for their use in non-cystic fibrosis bronchiectasis (hereafter, bronchiectasis). According to data extracted from large databases of bronchiectasis in adults, ICSs are used in more than 50% of patients without any scientific evidence to justify their efficacy and contrary to the recommendations of international guidelines on bronchiectasis that generally advise against their use. Indeed, bronchiectasis is a disease with predominantly neutrophilic inflammation and a high likelihood of chronic bacterial bronchial infection. Furthermore, it is known that due to their immunosuppressive properties, ICSs can induce an increase in bacterial infections. This manuscript aims to review the basic properties of ICSs, how they impact bronchiectasis in adults, the current position of international guidelines on this treatment, and the current indications and future challenges related to ICS use in bronchiectasis.
Identifiants
pubmed: 36264441
doi: 10.1007/s40265-022-01785-1
pii: 10.1007/s40265-022-01785-1
pmc: PMC9626424
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Anti-Bacterial Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1453-1468Informations de copyright
© 2022. The Author(s).
Références
Aliberti S, Goeminne PC, O’Donnell AE, Aksamit TR, Al-Jahdali H, Barker AF, et al. Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations. Lancet Respir Med. 2022;10(3):298–306.
doi: 10.1016/S2213-2600(21)00277-0
pubmed: 34570994
Lonni S, Chalmers JD, Goeminne PC, McDonnell MJ, Dimakou K, De Soyza A, et al. Etiology of non-cystic fbrosis bronchiectasis in adults and its correlation to disease severity. Ann Am Thorac Soc. 2015;12(12):1764–70.
pubmed: 26431397
pmcid: 5467084
Martinez-García MA, Villa C, Dobarganes Y, Girón R, Maíz L, García-Clemente M, Sibila O, et al. RIBRON: The Spanish Online Bronchiectasis Registry. Characterization of the first 1912 patients. Arch Bronconeumol. 2021;57(1):28–35.
pubmed: 32081438
Chalmers JD, Chotirmall SH. Bronchiectasis: new therapies and new perspectives. Lancet Respir Med. 2018;6(9):715–26.
doi: 10.1016/S2213-2600(18)30053-5
pubmed: 29478908
Fuschillo S, de Felice A, Balzano G. Mucosal infammation in idiopathic bronchiectasis: cellular and molecular mechanisms. Eur Respir J. 2008;31(2):396–406.
pubmed: 18238949
Martinez-Garcia MA, Posadas T, Sotgiu G, Blasi F, Saderi L, Aliberti S. Repeatability of circulating eosinophil measures and inhaled corticosteroids effect in bronchiectasis. A post hoc analysis of a randomized clinical trial. Arch Bronconeumol (Engl Ed). 2020;56(10):681–3.
pubmed: 32660708
Shoemark A, Shteinberg M, De Soyza A, Haworth C, Richardson H, Gao Y, et al. Characterisation of eosinophilic bronchiectasis: a European multicohort study. Am J Respir Crit Care Med. 2022;205(8):894–902.
pubmed: 35050830
Martinez-Garcia MA. Bronchiectasis and eosinophils. Arch Bronconeumol. 2021;57:671–2.
pubmed: 35699001
Monsó E. Look at the wood and not at the tree: the microbiome in chronic obstructive lung disease and cystic fibrosis. Arch Bronconeumol. 2020;56(1):5–6.
pubmed: 31160069
Cole PJ. Inflammation: a two-edged sword—the model of bronchiectasis. Eur J Respir Dis Suppl. 1986;147:6–15.
pubmed: 3533593
Posadas T, Oscullo G, Zaldivar E, Villa C, Dobarganes Y, Girón R, et al. C-reactive protein concentration in steady-state bronchiectasis: prognostic value of future severe exacerbations. Data from the Spanish Registry of Bronchiectasis (RIBRON). Arch Bronconeumol. 2021;57(1):21–7.
pubmed: 32331706
Saleh AD, Chalmers JD, De Soyza A, Fardon TC, Koustas SO, Scott J. The heterogeneity of systemic inflammation in bronchiectasis. Respir Med. 2017;127:33–9.
pubmed: 28502416
Chen CL, Huang Y, Yuan JJ, Li HM, Han XR, Martinez-Garcia MA, et al. The Roles of bacteria and viruses in bronchiectasis exacerbation: a prospective study. Arch Bronconeumol. 2020;56(10):621–9.
pubmed: 33994634
pmcid: 7528950
Martinez-Garcia MA, Miravitlles M. Bronchiectasis in COPD patients: more than a comorbidity? Int J Chron Obstruct Pulmon Dis. 2017;12:1401–11.
pubmed: 28546748
pmcid: 5436792
Crimi C, Ferri S, Campisi R, Crimi N. The link between asthma and bronchiectasis: state of the art. Respiration. 2020;99:463–76.
pubmed: 32464625
Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):1700629.
pubmed: 28889110
Martínez-García MÁ, Máiz L, Olveira C, Girón RM, de la Rosa D, Blanco M, et al. Spanish guidelines on treatment of bronchiectasis in adults. Arch Bronconeumol. 2018;54(2):88–98.
pubmed: 29128129
Hill AT, Sullivan AL, Chalmers JD, De Soyza A, Elborn JS, Floto RA, et al. British Thoracic Society guideline for bronchiectasis in adults. Thorax. 2019;74(Suppl 1):1–69.
pubmed: 30545985
Reddel HK, Bacharier LB, Bateman ED, Brighting CE, Brusselle GG, Buhl R, et al. Global Initiative for Asthma strategy 2021. Executive summary and rationale for key changes. Arch Bronconeumol. 2022;2022(58):35–51.
Plaza V, Blanco M, García G, Korta J, Molina J, Quirce S. Highlights of the Spanish Asthma Guidelines (GEMA), version 5.0. Arch Bronconeumol. 2022;57(1):11–2.
Plaza V, Gómez-Outes A, Quirce S, Alobid I, Álvarez C, Blanco M, et al. Discrepancies between GEMA and GINA in the classification of inhaled corticosteroids. Arch Bronconeumol. 2020;56:472–3.
pubmed: 35373761
Pizzichini E, Pizzichini MM, Gibson P, Parameswaran K, Gleich GJ, Berman L, et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med. 1998;158(5 Pt 1):1511–7.
pubmed: 9817701
Brightling CE, Monteiro W, Ward R, Parker D, Morgan MD, Wardlaw AJ, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2000;356(9240):1480–5.
pubmed: 11081531
Brightling CE, McKenna S, Hargadon B, Birring S, Green R, Siva R, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax. 2005;60(3):193–8.
pubmed: 15741434
pmcid: 1747331
Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662–71.
pubmed: 21680942
Bafadhel M, McCormick M, Saha S, McKenna S, Shelley M, Hargadon B, et al. Profiling of sputum inflammatory mediators in asthma and chronic obstructive pulmonary disease. Respiration. 2012;83(1):36–44.
pubmed: 21912093
The Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2022. Available at: https://goldcopd.org/ . Accessed 30 May 2022.
Miravitlles M, Calle M, Molina J, Almagro P, Tomás Gómez J, Trigueros JA, et al. Spanish COPD guidelines (GesEPOC) 2021: Updated pharmacological treatment of stable COPD. Arch Bronconeumol. 2022;58(1):69–81.
pubmed: 33840553
Miravitlles M, Calle M, Soler-Cataluña JJ. GesEPOC 2021: One more step towards personalized treatment of COPD. Arch Bronconeumol. 2021;57(1):9–10.
pubmed: 32980163
Gaga M, Bentley AM, Humbert M, Barkans J, O’Brien F, Wathen CG, et al. Increases in CD4+ T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis. Thorax. 1998;53:685–91.
pubmed: 9828857
pmcid: 1745299
Angrill J, Agustí C, de Celis R, Rañó A, Gonzalez J, Solé T. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax. 2022;57:15–9.
Guan WJ, Gao YH, Xu G, Lin ZY, Tang Y, Gu YY. Sputum matrix metalloproteinase-8 and -9 and tissue inhibitor of metalloproteinase-1 in bronchiectasis: clinical correlates and prognostic implications. Respirology. 2015;20:1073–81.
pubmed: 26122009
Boyton RJ, Altmann DM. Bronchiectasis: current concepts in pathogenesis, immunology, and microbiology. Annu Rev Pathol. 2016;11:523–54.
pubmed: 26980162
King PT. The pathophysiology of bronchiectasis. Int J Chron Obstruct Pulmon Dis. 2009;4:411–9.
pubmed: 20037680
pmcid: 2793069
Tsikrika S, Dimakou K, Papaioannou AI, Hillas G, Thanos L, Kostikas K, et al. The role of non-invasive modalities for assessing inflammation in patients with non-cystic fibrosis bronchiectasis. Cytokine. 2017;99:281–6.
pubmed: 28863927
Ravin KA, Loy M. The eosinophil in infection. Clin Rev Allerg Immunol. 2016;50:214–27.
King PT, Daviskas E. Pathogenesis and diagnosis of bronchiectasis. Breathe. 2010;6:341–51.
de la Rosa CD, López-Campos JL, Alcázar Navarrete B, Calle Rubio M, Cantón Moreno R, García-Rivero JL, et al. Consensus document on the diagnosis and treatment of chronic bronchial Infection in chronic obstructive pulmonary disease. Arch Bronconeumol. 2020;56(10):651–64.
Flume PA, Chalmers JD, Olivier KN. Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity. Lancet. 2018;392(10150):880–90.
pubmed: 30215383
pmcid: 6173801
De la Rosa D, Martinez-Garcia MA, Barreiro E, Tabernero E, Costa R, Garcia-Clemente M, et al. Effectiveness and safety of inhaled antibiotics in patients with chronic obstructive pulmonary disease. A multicentre observational study. Arch Bronconeumol. 2022;58(1):11–21.
Mac Aogáin M, Narayana JK, Tiew PY, Ali NABM, Yong VFL, Jaggi TK, et al. Integrative microbiomics in bronchiectasis exacerbations. Nat Med. 2021;27(4):688–99.
pubmed: 33820995
Richardson H, Dicker AJ, Barclay H, Chalmers JD. The microbiome in bronchiectasis. Eur Respir Rev. 2019;28: 190048.
pubmed: 31484665
Araújo D, Shteinberg M, Aliberti S, Goeminne PC, Hill AT, Fardon TC, et al. The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis. Eur Respir J. 2018;51(2):1701953.
pubmed: 29386336
Finch S, McDonnell MJ, Abo-Leyah H, Aliberti S, Chalmers JD. A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Ann Am Thorac Soc. 2015;12(11):1602–11.
pubmed: 26356317
Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med. 2014;189(5):576–85.
pubmed: 24328736
pmcid: 3977711
Martínez-García MA, Soler-Cataluña JJ, Perpiñá-Tordera M, Román-Sánchez P, Soriano J. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest. 2007;132(5):1565–72.
pubmed: 17998359
Dhar R, Singh S, Talwar D, Mohan M, Kant Tripathi S, Swarnakar R, et al. Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry. Lancet Glob Health. 2019;7(9):e1269–79.
pubmed: 31402007
Martinez-Garcia MA, Athanazio RA, Girón R, Máiz-Carro L, de la Rosa D, Olveira C, et al. Predicting high risk of exacerbations in bronchiectasis: the E-FACED score. Int J Chron Obstruct Pulmon Dis. 2017;12:275–84.
pubmed: 28182132
pmcid: 5279836
Aksamit TR, O’Donnell AE, Barker A, Olivier KN, Winthrop KL, Daniels MLA, et al. Bronchiectasis Research Registry Consortium. Adult patients with bronchiectasis: a first look at the US Bronchiectasis Research Registry. Chest. 2017;15:982–92.
Lasserson T, Holt K, Greenstone M. Oral steroids for bronchiectasis (stable and acute exacerbations). Cochrane Database Syst Rev. 2001;2001(4):C002162.
Barnes PJ. Glucocorticosteroids. Handb Exp Pharmacol. 2017;237:93–115.
pubmed: 27796513
Caramori G, Nucera F, Mumby S, Lo Bello F, Adcock IM. Corticosteroid resistance in asthma: cellular and molecular mechanisms. Mol Aspects Med. 2022;85: 100969.
pubmed: 34090658
Strehl C, Buttgereit F. Optimized glucocorticoid therapy: teaching old drugs new tricks. Mol Cell Endocrinol. 2013;380(1–2):32–40.
pubmed: 23403055
De Bosscher K, Haegeman G. Minireview: latest perspectives on antiinflammatory actions of glucocorticoids. Mol Endocrinol. 2009;23(3):281–91.
pubmed: 19095768
pmcid: 5428155
Clark AR, Belvisi MG. Maps and legends: the quest for dissociated ligands of the glucocorticoid receptor. Pharmacol Ther. 2012;134(1):54–67.
pubmed: 22212616
Panettieri RA, Schaafsma D, Amrani Y, Koziol-White C, Ostrom R, Tliba O. Non-genomic effects of glucocorticoids: an updated view. Trends Pharmacol Sci. 2019;40(1):38–49.
pubmed: 30497693
Sabroe I, Postma D, Heijink I, Dockrell DH. The yin and the yang of immunosuppression with inhaled corticosteroids. Thorax. 2013;68(12):1085–7.
pubmed: 23929790
Adcock IM, Mumby S. Glucocorticoids. Handb Exp Pharmacol. 2017;237:171–96.
pubmed: 27864677
Singh S, Pragman AA, Segal LN. Balancing benefits and risks: do inhaled corticosteroids modify the lung microbiome? Am J Respir Crit Care Med. 2021;204(10):1117–9.
pubmed: 34554893
pmcid: 8759301
O’Sullivan S, Cormican L, Burke CM, Poulter LW. Fluticasone induces T cell apoptosis in the bronchial wall of mild to moderate asthmatics. Thorax. 2004;59(8):657–61.
pubmed: 15282384
pmcid: 1747107
Demedts IK, Demoor T, Bracke KR, Joos GF, Brusselle GG. Role of apoptosis in the pathogenesis of COPD and pulmonary emphysema. Respir Res. 2006;7(1):53.
pubmed: 16571143
pmcid: 1501017
Stolberg VR, McCubbrey AL, Freeman CM, Brown JP, Crudgington SW, Taitano SH, et al. Glucocorticoid-augmented efferocytosis inhibits pulmonary pneumococcal clearance in mice by reducing alveolar macrophage bactericidal function. J Immunol. 2015;195(1):174–84.
pubmed: 25987742
Keir HR, Contoli M, Chalmers JD. Inhaled corticosteroids and the lung microbiome in COPD. Biomedicines. 2021;9(10):1312.
pubmed: 34680429
pmcid: 8533282
Angrill J, Agustí C, de Celis R, Rañó A, Gonzalez J, Solé T, et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax. 2002;57(1):15–9.
pubmed: 11809984
pmcid: 1746176
Tsang KW, Tan KC, Ho PL, Ooi GC, Ho JC, Mak J, et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax. 2005;60(3):239–43.
pubmed: 15741443
pmcid: 1747352
Daley-Yates PT. Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br J Clin Pharmacol. 2015;80(3):372–80.
pubmed: 25808113
pmcid: 4574823
Matera MG, Rinaldi B, Calzetta L, Rogliani P, Cazzola M. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment. Pulm Pharmacol Ther. 2019;58: 101828.
pubmed: 31349002
Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J. 2006;28(5):1042–50.
pubmed: 17074919
Winkler J, Hochhaus G, Derendorf H. How the lung handles drugs: pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Thorac Soc. 2004;1(4):356–63.
pubmed: 16113458
Rossi GA, Cerasoli F, Cazzola M. Safety of inhaled corticosteroids: room for improvement. Pulm Pharmacol Ther. 2007;20(1):23–35.
pubmed: 16359896
Kelly HW. Comparison of inhaled corticosteroids: an update. Ann Pharmacother. 2009;43(3):519–27.
pubmed: 19261959
Ye Q, He XO, D’Urzo A. A review on the safety and efficacy of inhaled corticosteroids in the management of asthma. Pulm Ther. 2017;3(1):1–18.
Hübner M, Hochhaus G, Derendorf H. Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin North Am. 2005;25(3):469–88.
pubmed: 16054538
Borghardt JM, Weber B, Staab A, Kloft C. Pharmacometric models for characterizing the pharmacokinetics of orally inhaled drugs. AAPS J. 2015;17(4):853–70.
pubmed: 25845315
pmcid: 4477002
Johnson M. Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. J Allergy Clin Immunol. 1996;97(1 Pt 2):169–76.
pubmed: 8568148
Freiwald M, Valotis A, Kirschbaum A, McClellan M, Mürdter T, Fritz P, et al. Monitoring the initial pulmonary absorption of two different beclomethasone dipropionate aerosols employing a human lung reperfusion model. Respir Res. 2005;6(1):21.
pubmed: 15727687
pmcid: 555845
Kelly HW. Pharmaceutical characteristics that influence the clinical efficacy of inhaled corticosteroids. Ann Allergy Asthma Immunol. 2003;91(4):326–34.
pubmed: 14582810
Bäckman P, Adelmann H, Petersson G, Jones CB. Advances in inhaled technologies: understanding the therapeutic challenge, predicting clinical performance, and designing the optimal inhaled product. Clin Pharmacol Ther. 2014;95(5):509–20.
pubmed: 24503626
Miller-Larsson A, Mattsson H, Hjertberg E, Dahlbäck M, Tunek A, Brattsand R. Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos. 1998;26(7):623–30.
pubmed: 9660844
Nave R, Meyer W, Fuhst R, Zech K. Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pulm Pharmacol Ther. 2005;18(6):390–6.
pubmed: 16179214
Allen DB, Bielory L, Derendorf H, Dluhy R, Colice GL, Szefler SJ. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol. 2003;112(3 Suppl):S1–40.
pubmed: 14515117
Allen A, Bareille PJ, Rousell VM. Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. Clin Pharmacokinet. 2013;52(1):37–42.
pubmed: 23184737
Wang P, Wang X, Yang X, Liu Z, Wu M, Li G. Budesonide suppresses pulmonary antibacterial host defense by down-regulating cathelicidin-related antimicrobial peptide in allergic inflammation mice and in lung epithelial cells. BMC Immunol. 2013;14:7.
pubmed: 23387852
pmcid: 3583690
Dowling RB, Johnson M, Cole PJ, Wilson R. Effect of fluticasone propionate and salmeterol on Pseudomonas aeruginosa infection of the respiratory mucosa in vitro. Eur Respir J. 1999;14(2):363–9.
pubmed: 10515415
Martínez-García MA, Perpiñá-Tordera M, Román-Sánchez P, Soler-Cataluña JJ. Inhaled steroids improve quality of life in patients with steady-state bronchiectasis. Respir Med. 2006;100(9):1623–32.
pubmed: 16434174
Hernando R, Drobnic ME, Cruz MJ, Ferrer A, Suñé P, Montoro JB, et al. Budesonide efficacy and safety in patients with bronchiectasis not due to cystic fibrosis. Int J Clin Pharm. 2012;34(4):644–50.
pubmed: 22684355
Kapur N, Petsky HL, Bell S, Kolbe J, Chang AB. Inhaled corticosteroids for bronchiectasis. Cochrane Database Syst Rev. 2018;5(5):CD000996.
pubmed: 29766487
Tsang KW, Ho PL, Lam WK, Ip MS, Chan KN, Ho CS, et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am J Respir Crit Care Med. 1998;158(3):723–7.
pubmed: 9730996
Håkansson KEJ, Fjaellegaard K, Browatzki A, Dönmez Sin M, Ulrik CS. Inhaled corticosteroid therapy in bronchiectasis is associated with all-cause mortality: a prospective cohort study. Int J Chron Obstruct Pulmon Dis. 2021;16:2119–27.
pubmed: 34295156
pmcid: 8291380
Henkle E, Aksamit TR, Barker AF, Curtis JR, Daley CL, Anne Daniels ML, et al. Pharmacotherapy for non-cystic fibrosis bronchiectasis: results from an NTM Info & Research Patient Survey and the Bronchiectasis and NTM Research Registry. Chest. 2017;152(6):1120–7.
pubmed: 28479113
pmcid: 6026272
Henkel E, Chan B, Aksamit TR, Curtis JR, Winthrop KL. Factors associated with extended inhaled corticosteroid use in US Medicare bronchiectasis patients. Am J Respir Crit Care Med. 2018;197:A6282.
Wei P, Yang JW, Lu HW, Mao B, Yang WL, Xu JF. Combined inhaled corticosteroid and long-acting β2-adrenergic agonist therapy for noncystic fibrosis bronchiectasis with airflow limitation: an observational study. Medicine (Baltimore). 2016;95(42): e5116.
Loukides S, Horwarth I, Wodehouse T, Coler PJ, Barnes PJ. Elevated levels of expired breath hydrogen peroxide in bronchiectasis. Am J Respir Crit Care Med. 1998;168:991–4.
Tsang KW, Tan KC, Ho PL, Ooi GC, Khong PL, Leung R, et al. Exhaled nitric oxide in bronchiectasis: the effects of inhaled corticosteroid therapy. Int J Tuberc Lung Dis. 2004;8:1301–7.
pubmed: 15581196
Hernando R, Drobnic ME, Cruz MJ, Ferrer A, Suñe P, Montoro J, et al. Budesonide efficacy and safety in patients with bronchiectasis not due to cystic fibrosis. Int J Clin Pharm. 2012;34:644–50.
pubmed: 22684355
Martinez-Garcia MA, Posadas T, Sotgiu G, Blasi F, Saderi L, Aliberti A. Role of inhaled corticosteroids in reducing exacerbations in bronchiectasis patients with blood eosinophilia pooled post-hoc analysis of 2 randomized clinical trials. Resp Med. 2020;172: 106127.
Ilowite J, Spiegler P, Kessler H. Pharmacological treatment options for bronchiectasis: focus on antimicrobial and anti-inflammatory agents. Drugs. 2009;69(4):407–19.
pubmed: 19323585
Elborn JS, Johnston B, Allen F, Clarke J, McGarry J, Varguese G. Inhaled steroids in patients with bronchiectasis. Respir Med. 1992;86:121–4.
pubmed: 1615177
Martinez-Garcia MA, Perpina-Tordera M, Roman-Sanchez P, et al. Inhaled steroids improve quality of life in patients with steady-state bronchiectasis. Respir Med. 2006;100:1623–32.
pubmed: 16434174
Joshi JM, Sundaram P. Role of inhaled steroids in stable bronchiectasis. Indian Pract. 2004;57(4):243–5.
Martínez-García MÁ, Soler-Cataluña JJ, Catalán-Serra P, Román-Sánchez P, Tordera MP. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest. 2012;141:461–8.
pubmed: 21778259
Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;168:1029–36.
Andrejak C, Nielsen R, Thomsen VØ, Duhaut P, Sørensen HT, Thomsen RW. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax. 2013;68:256–62.
pubmed: 22781123
Eklöf J, Ingebrigtsen TS, Sorensen R, Isam Saeed M, Alispahic IA, Sivapalan P, et al. Use of inhaled corticosteroids and risk of acquiring Pseudomonas aeruginosa in patients with chronic obstructive pulmonary disease. Thorax. 2022;77:573–80.
pubmed: 34446524
Lee JK, Lee J, Park SS, Heo EY, Park YS, Lee CH, et al. Effect of inhalers on the development of haemoptysis in patients with non-cystic fibrosis bronchiectasis. Int J Tuberc Lung Dis. 2014;18:363–70.
pubmed: 24670577
Holme J, Tomlinson JW, Stockley RA, Steward PM, Barlow N, Sullivan AL. Adrenal suppression in bronchiectasis and the impact of inhaled corticosteroids. Eur Resp J. 2008;32:1047–52.
Chalmers JD, Boersma W, Lonergan M, Jayaram L, Crichton ML, Karalus N. Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis. Lancet Respir Med. 2019;7(10):845–54.
pubmed: 31405828
Henkle E, Curtis JR, Chen L, Chan B, Aksamit TR, Daley CL, et al. Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis. Eur Respir J. 2019;54(1):1801896.
pubmed: 31000676
Henkle E, Daley CL, Curtis JR, Chan B, Aksamit TR, Winthrop KL. Comparative safety of inhaled corticosteroids and macrolides in Medicare enrolees with bronchiectasis. ERJ Open Res. 2022;8(1):00786–2020.
pubmed: 35265701
pmcid: 8899493
Al-Jahdali H, Alshimemeri A, Mobeireek A, Albanna AS, Al Shirawi NN, Wali S, et al. The Saudi Thoracic Society guidelines for diagnosis and management of noncystic fibrosis bronchiectasis. Ann Thorac Med. 2017;12(3):135–61.
pubmed: 28808486
pmcid: 5541962
Chang AB, Bell SC, Torzillo PJ, King PT, Maguire GP, Byrnes CA, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Thoracic Society of Australia and New Zealand guidelines. Med J Aust. 2015;202(1):130.
pubmed: 25669469
Padilla A, Olveira C, Fernandez L, Marco I, Plata AJ, Alvarez A, et al. Factors associated with bronchiectasis in patients with uncontrolled asthma; the NOPES score: a study in 398 patients. Respir Res. 2018;19(1):43.
Polverino E, Dimakou K, Hurst J, Martinez-Garcia MA, Miravitlles M, Paggiaro P, et al. The overlap between bronchiectasis and chronic airways diseases: state of the art and future directions. Eur Respir J. 2018;52(3):1800328.
pubmed: 30049739
Du Q, Jin J, Liu X, Sun Y. Bronchiectasis as a comorbidity of chronic obstructive pulmonary disease: a systematic review and meta-analysis. PLoS ONE. 2016;11(3): e0150532.
pubmed: 26978269
pmcid: 4792534
Singanayagam A, Glanville N, Girkin JL, Ching YM, Marcellini A, Porter JD, et al. Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations. Nat Commun. 2018;9(1):2229.
pubmed: 29884817
pmcid: 5993715
Singanayagam A, Johnston SL. Long-term impact of inhaled corticosteroid use in asthma and chronic obstructive pulmonary disease (COPD): Review of mechanisms that underlie risks. J Allergy Clin Immunol. 2020;146(6):1292–4.
pubmed: 31953103
Singanayagam A, Glanville N, Cuthbertson L, Bartlett NW, Finney LJ, Turek E, et al. Inhaled corticosteroid suppression of cathelicidin drives dysbiosis and bacterial infection in chronic obstructive pulmonary disease. Sci Transl Med. 2019;11(507):eaav3879.
pubmed: 31462509
pmcid: 7237237
Cazzola M, Ora J, Calzetta L, Rogliani P, Matera MG. Advances in inhaled corticosteroids for the treatment of chronic obstructive pulmonary disease: what is their value today? Expert Opin Pharmacother. 2022;23(8):917–27.
pubmed: 35575510
Martinez-Garcia MA, Faner R, Oscullo G, de la Rosa D, Soler JJ, Ballester M, et al. Inhaled steroids, circulating eosinophils, chronic airway infection, and pneumonia risk in chronic obstructive pulmonary disease. A Network Analysis. Am J Respir Crit Care Med. 2020;201:1079–85.
Aliberti S, Sotgiu G, Blasi F, Saderi L, Posadas T, Martinez-Garcia MA. Blood eosinophils predict inhaled fluticasone response in bronchiectasis. Eur Respir J. 2020;56(2):2000453.
pubmed: 32398295
Cosio BG, Shafiek H, Martinez-Garcia MA. Is it time to readjust the doses of inhaled corticosteroids in COPD? Arch Bronconeumol. 2022;58(8):593–4. https://doi.org/10.1016/j.arbres.2022.01.014 .
doi: 10.1016/j.arbres.2022.01.014
pubmed: 35484016
Visser SK, Bye PTP, Fox GJ, Burr LD, Chang AB, et al. Australian adults with bronchiectasis: The first report from the Australian Bronchiectasis Registry. Resp Med. 2019;155:97–103.
Lee H, Dhar R, Oh YM. Characteristics of bronchiectasis in Korea: First data from the Korean Multicentre Bronchiectasis Audit and Research Collaboration registry and comparison with other international registries. Respirology. 2021;26:618–20.
Polverino E, Chalmers JD, Aliberti S, Haworth C, Blasi F, Boersma W, et al. Inhaled corticosteroids use in patients with bronchiectasis: Data from the EMBARC registry. Eur Resp J. 2021;58:OA1312.
O’Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax. 2000;55:635–42.
pubmed: 10899238
pmcid: 1745831
Martinez-Garcia MA, Oscullo G, Garcia-Ortega A, Matera MG, Rogliani P, Cazzola M. Rationale and clinical use of bronchodilators in adults with bronchiectasis. Drugs. 2022;82(1):1–13.
pubmed: 34826104
Monteagudo M, Nuñez A, Solntseva I, Dhalwani N, Booth A, Barrecheguren M, et al. Treatment pathways before and after triple therapy in COPD: a population-based study in primary care in Spain. Arch Bronconeumol. 2021;57:205–13.
pubmed: 33004238
López-Campos JL, Carrasco-Hernández L, Román Rodríguez L, Quintana-Gallego E, Carmona Bernal C, Alcázar NB. The clinical implications of triple therapy in fixed-dose combination in COPD: from the trial to the patient. Arch Bronconeumol. 2020;56(4):242–8.
pubmed: 35373739
Ruano-Raviña A, Fernández-Villar A, López-Campos JL. Coping with low mortality and exacerbation rate differences between COPD triple therapy studies, and a proposal for upcoming studies. Arch Bronconeumol. 2020;56(5):336–8.
pubmed: 31898995